

Key targets and mechanistic insights affecting radiotherapy effectiveness in renal carcinoma patients with concurrent renal failure

J. Wei^{1#}, P. Gao^{1#}, Z. Wang², L. Fan³, J. Zhao^{1*}

¹Department of Nephrology, Zibo First Hospital, Zibo Shandong, China

²Department of Chinese Medicine, Zibo First Hospital, Zibo Shandong, China

³Hemodialysis Center, Zibo First Hospital, Zibo Shandong, China

► Original article

ABSTRACT

*Corresponding author:

Jin Zhao, M.D.,

E-mail:

zhaojin8490@dingtalk.com

Received: February 2025

Final revised: April 2025

Accepted: May 2025

Int. J. Radiat. Res., October 2025;
23(4): 839-845

DOI: 10.61186/ijrr.23.4.2

Background: To explore the key targets and regulatory mechanisms affecting the efficacy of radiotherapy (RT) in patients with renal carcinoma (RCC) complicated by renal failure. **Materials and Methods:** Differentially expressed genes (DEGs) ($|\log_2FC| > 2$) in TCGA (n=537) and GEO data set (n=215) were screened by limma package in R software. Intersecting genes were accessed through the online site (InteractiVenn). The STRING and MCODE module of the Metascape website were used for key target screening and enriched pathway analysis. The preprocessCore R package was used for data normalization and batch effect processing. The survival/survminer R package was used to analyze the relationship between gene expression and patient survival. **Results:** High expression of ACADM, DLAT, SUCLA2 and SUCLG2 genes were all associated with significantly improved prognosis in renal cancer patients. The mOS time in the ACADM high expression group was 7.10 years [Hazard Ratio (HR) = 0.466, 95% Confidence Interval (CI): 0.353-0.615]. The mOS time in the DLAT high expression group was 7.10 years (HR=0.489, 95% CI: 0.372-0.642). The mOS time in the SUCLA2 high expression group was 7.30 years (HR=0.458, 95% CI: 0.346-0.606). The mOS time in the SUCLG2 group was 7.00 years (HR=0.544, 95% CI: 0.415-0.715). **Conclusion:** The suppression of ACADM, DLAT, SUCLA2, and SUCLG2 can regulate fatty acid metabolism and tricarboxylic acid cycle-related pathways, which provides ideas for the prognosis of patients with RCC complicated by renal failure.

Keywords: Prognosis, radiotherapy, renal carcinoma, renal failure.

#Jie Wei, and Pan Gao contributed equally to this work and should be considered co-first authors.

INTRODUCTION

Renal carcinoma (RCC) ranks among the most prevalent malignancies affecting the urinary system. There were 431,288 new cases of RCC and 179,368 deaths in 2020 in the whole world ^(1,2). According to pathological features, RCC is primarily divided into clear cell renal cell carcinoma (ccRCC) and non-clear cell renal cell carcinoma (nccRCC), with a higher proportion of ccRCC patients. The spread of awareness of medical checkups and advances in testing technology have reduced the mortality rate of RCC patients, but the treatment outcome is not as good as expected ⁽³⁾. Heterogeneity and drug resistance result in objective remission rates of less than 40% in patients with advanced ccRCC treated with standard regimens ^(4,5). There is a complex bidirectional association between renal failure and RCC ⁽⁶⁾. On the one hand, researchers believe that the high risk of RCC in patients with renal failure may be related to the long-term inflammatory microenvironment of the body, while metabolic disorders ⁽⁷⁾ and immune function inhibition leading to cell damage, DNA mutation and accumulation of

toxic substances should not be ignored ^(8,9). On the other hand, RCC patients who have received clinical treatment are prone to show compensatory hypertrophy of renal units and overload of renal function, which can trigger the deterioration of renal function to form a "tumor-renal failure" cycle ^(10,11). Clinical evidence in patients with RCC complicated by renal failure is limited, and the key targets and mechanisms of onset of action that influence the prognosis of this group are currently unclear ⁽¹²⁾. Surgery is the main treatment modality for kidney cancer patients, and non-surgical treatment modalities such as stereotactic body radiation therapy (SBRT) are also clinical options ⁽¹³⁾. The combination of radiotherapy and immunotherapy has emerged as a research frontier, as radiotherapy modulates the tumor microenvironment to enhance immune cell recruitment and activation, synergizing with immune checkpoint inhibitors ⁽¹⁴⁾. Clinical trials report promising disease control in metastatic RCC with combined radiotherapy and immunotherapy ⁽¹⁵⁾. Furthermore, radiotherapy demonstrates efficacy in surgically ineligibly locally advanced RCC, where SBRT achieves robust local control with minimal

toxicity⁽¹⁶⁾, and may be combined with tyrosine kinase inhibitors (TKIs) to amplify therapeutic outcomes⁽¹⁷⁾. However, renal failure patients with impaired kidney function often exhibit heightened oxidative stress, compromised DNA repair capacity, and dysregulated immune microenvironments, potentially exacerbating radiotherapy toxicities such as radiation nephritis or myelosuppression^(18, 19). Current clinical guidelines lack specific radiotherapy recommendations for this high-risk cohort, and systematic investigations into shared molecular targets between renal carcinoma radiotherapy resistance and renal failure progression remain absent, severely hindering the development of precision therapeutic strategies.

In this study, we integrated the transcriptomic data from TCGA and GEO databases to identify for the first time the prognostic targets affecting radiotherapy in patients with RCC and renal failure. These targets may become a “molecular bridge” connecting the resistance to RT in RCC and the progression of renal failure, providing a basis for optimizing the RT regimen for patients with renal failure combined with RCC and a new perspective for translational medicine.

MATERIALS AND METHODS

TCGA data selection

Transcriptomic data and clinical information for renal carcinoma samples were retrieved from TCGA database (<https://portal.gdc.cancer.gov>). Gene expression data in transcripts per million (TPM) format were extracted and normalized using $\log_2(\text{TPM} + 1)$ transformation⁽²⁰⁾. Samples with complete RNA sequencing (RNA-seq) data and clinical annotations were included for subsequent analyses.

GEO dataset processing

Data from the GEO database were downloaded in MINiML format. For datasets lacking normalization, \log_2 transformation was uniformly applied. Datasets lacking normalization were standardized using the `normalize.quantiles` function from the `preprocessCore` package in R/Bioconductor (<http://www.bioconductor.org/packages/3.0/bioc/html/preprocessCore.html>). Probes associated with multiple genes were excluded using platform annotation files, and the expression values for genes with multiple probes were averaged. The `removeBatchEffect` function from the `limma` package in R was utilized to correct batch effects⁽²¹⁾.

Differential gene expression analysis

were identified using the `limma` package (v3.40.2) in R. Adjusted P-values were calculated to control false discovery rates (FDR) in TCGA and GTEX datasets. DEGs were identified by a $|\log_2(\text{fold}$

change)| greater than 2 and an adjusted P-value less than 0.05. Gene expression heatmaps were created using the `heatmap` package (v1.0.12)⁽²²⁾. For visualization, genes with variance > 0.1 were prioritized. If the number of candidate genes exceeded 1,000, the top 25% of genes with the highest variance were selected. Statistical analyses were conducted using R (v4.0.3), with significance set at $P < 0.05$.

Identification of overlapping DEGs

DEG lists from renal carcinoma and renal failure cohorts were imported into the InteractiVenn web tool (<http://www.interactivenn.net/>) to identify overlapping genes through interactive multi-set visualization. Overlapping genes were strictly validated by matching both gene symbols and Ensembl IDs to exclude false positives caused by annotation discrepancies.

STRING/Metascape functional analysis

PPI and functional annotations were developed using the STRING database (<https://cn.string-db.org/>) with high-confidence interactions (score ≥ 0.7). Core functional modules were identified using the MCODE algorithm with a score threshold of 3 or higher, and enriched pathways were determined with a false discovery rate (FDR) below 0.05. Pathway and process enrichment analyses were conducted using Metascape (<https://metascape.org/gp/index.html>) with the Gene Prioritization by Evidence Counting (GPEC) method. The parameters were set to a minimum overlap of 3, a P-value cutoff of 0.01, and a minimum enrichment of 1.5.

Survival analysis

Genes with high centrality scores in PPI networks were subjected to survival analysis in renal carcinoma patients. The log-rank test ($P < 0.05$) was used to evaluate survival differences between groups. Calculated hazard ratios (HRs) with 95% confidence intervals (CIs) and median survival times (years). The analyses utilized the `survival` and `survminer` packages (v4.0.3) in R⁽²³⁾.

RESULTS

DEGs in TCGA renal carcinoma radiotherapy cohort

Analysis of 26 radiotherapy-treated renal carcinoma samples and 128 adjacent normal tissues from TCGA identified 993 upregulated and 1,650 downregulated DEGs. Notably, genes such as *TMEM213*, *KCNJ1*, and *KNG1* exhibited significant expression changes in renal failure samples, suggesting their potential roles in renal pathology (figure 1A).




Figure 1. presents an intersection analysis of differentially expressed genes associated with RCC and renal failure (A, Volcano plot; B, Intersection of differentially expressed genes for RCC and renal failure).

Functional enrichment of TCGA radiotherapy-related DEGs

Gene Ontology (GO) enrichment analysis of TCGA radiotherapy-related differentially expressed genes (DEGs) indicated that upregulated genes were significantly linked to biological processes such as T-cell activation, leukocyte proliferation, and regulation of cell-cell adhesion. Molecular functions (MF) enriched cytokine binding, carbohydrate binding, and immune receptor activity. Cellular component (CC) analysis highlighted chromosomal centromeric regions, endoplasmic reticulum lumen, and secretory granule membranes. The top three pathways in terms of significance were shown in figure 2A. KEGG pathway analysis revealed that upregulated genes were enriched in the phagosome, cytokine-cytokine receptor interaction, and NF- κ B signaling pathways. The more significant pathways were shown in figure 2B. Downregulated genes were linked to organic acid catabolism, kidney development, and sodium ion homeostasis, transmembrane transporter activity and mitochondrial matrix. The top three pathways in terms of significance were shown in figure 2C. KEGG pathways for downregulated genes included valine, leucine, and isoleucine degradation, carbon metabolism, and PPAR signaling. The more significant pathways were shown in figure 2D.

GEO renal failure DEGs

Analysis of dataset GSE37171 (GPL570 platform, 75 renal failures vs. 40 normal samples) identified 39 upregulated and 502 downregulated DEGs⁽²⁴⁾.

Overlapping DEGs between renal carcinoma and renal failure

Intersection analysis revealed 4 upregulated (*ZNF205*, *PLEKHN1*, *S100A8*, and *VWCE*) and 29 downregulated genes (*ACAD8*, *SUCLG2*, *BEX4*, *DLAT*, *PRMT6*, *TSPYL4*, *FOS*, *AK3*, *SGPP1*, *GPRASP1*, *CIPC*, *NR1D2*, *TBC1D4*, *SUCLA2*, *AMIGO2*, *ACADM*, *BLNK*, *MICU2*, *ARHGEF3*, *SGMS1*, *ATP6V1A*, *PTGER4*, *UBL3*, *GCH1*, *SACM1L*, *HLTF*, *KLHL2* and *MAN1A1*) shared between renal carcinoma radiotherapy and renal failure cohorts (figure 1B).




Figure 2. presents the functional and pathway enrichment analysis of genes differentially expressed due to RT in RCC. (A, GO analysis of up-regulated genes; B, KEGG analysis of up-regulated genes; C, GO analysis of down-regulated genes; D, KEGG analysis of down-regulated genes).

Core gene identification

STRING analysis identified *ACADM*, *DLAT*, *SUCLA2*, and *SUCLG2* as hub genes with high node degrees (figure 3, table 1). These genes were prioritized as core regulators influencing radiotherapy outcomes in renal carcinoma patients with renal failure.

Table 1. Core genes identified via STRING database.

Node	Identifier	Node Degree
<i>ACADM</i>	9606.ENSP00000359871	3
<i>DLAT</i>	9606.ENSP00000280346	4
<i>SUCLA2</i>	9606.ENSP00000494360	4
<i>SUCLG2</i>	9606.ENSP00000419325	3

Note: Acyl-CoA Dehydrogenase Medium Chain, *ACADM*; Dihydroipoamide S-Acetyltransferase, *DLAT*; Succinate-CoA Ligase ADP-Forming Subunit Beta, *SUCLA2*; Succinate-CoA Ligase GDP-Forming Subunit Beta, *SUCLG2*.

Pathway enrichment of core genes

GO-MF analysis enriched ligase activity, GTP binding, and calcium ion binding. GO-BP highlighted tricarboxylic acid (TCA) cycle, response

to lipopolysaccharide, and lipid modification. GO-CC terms included mitochondrial matrix and Golgi membrane. KEGG pathways showed significant enrichment in citrate cycle (TCA cycle) and metabolic pathways (table 2).




Figure 3. Core gene selection based on string database.

Table 2. Enriched pathways of core genes.

Category	Term ID	Description	LogP
GO-MF	GO:0016874	Ligase activity	-6.068
	GO:0005525	GTP binding	-3.198
	GO:0005509	Calcium ion binding	-2.259
GO-BP	GO:0006099	Tricarboxylic acid cycle	-6.234
	GO:0032496	Response to lipopolysaccharide	-3.311
	GO:0030258	Lipid modification	-3.099
	GO:0005975	Carbohydrate metabolic process	-2.872
	GO:0070482	Response to oxygen levels	-2.200
GO-CC	GO:0005759	Mitochondrial matrix	-4.730
	GO:0000139	Golgi membrane	-2.180
KEGG	hsa00020	Citrate cycle (TCA cycle)	-5.329
	hsa01100	Metabolic pathways	-3.257

Note: GO, Ontology; MF, Molecular Function; BP, Biological Process; CC, Cellular Component; KEGG, Kyoto Encyclopedia of Genes and Genomes; TCA, Tricarboxylic Acid cycle.

Prognostic significance of core genes

Survival analysis demonstrated that high expression of *ACADM* (median survival: 7.1 years; HR = 0.466, 95% CI: 0.353–0.615; P < 0.05; figure 4A), *DLAT* (HR = 0.489, 95% CI: 0.372–0.642; P < 0.05; figure 4B), *SUCLA2* (median survival: 7.3 years; HR = 0.458, 95% CI: 0.346–0.606; P < 0.05; figure 4C), and *SUCLG2* (median survival: 7.0 years; HR = 0.544, 95% CI: 0.415–0.715; P < 0.05; figure 4D) correlated with improved overall survival in renal carcinoma patients.




Figure 4. Survival analysis of *ACADM*, *DLAT*, *SUCLA2*, and *SUCLG2* in TCGA RCC cohort (A, *ACADM*; B, *DLAT*; C, *SUCLA2*; D, *SUCLG2*).

DISCUSSION

We analyzed RT data from public databases of patients with RCC complicated by renal failure, and found that *ACADM*, *DLAT*, *SUCLA2* and *SUCLG2* may affect patient prognosis by regulating the mitochondrial tricarboxylic acid cycle (TCA cycle) and energy metabolic pathways. Cancer patients with renal insufficiency may face higher toxicity and cardiovascular risks when receiving treatment, but individualized treatment strategies may help to reduce renal damage. Nouhaud *et al.* (25) concluded that patients with renal insufficiency may face a higher risk of toxicity when receiving tumor therapy, which in turn affects the tolerability and efficacy of the treatment. Zhang *et al.* (26) showed that patients with poorer renal function may be at a higher risk of cardiovascular events after receiving tumor therapy, and that certain radiotherapy techniques are able to reduce the risk of further renal damage. However, Ohno *et al.* (6,27) suggested that in some cases surgery or targeted therapy could avoid the phenomenon of RT-induced deterioration of renal function. We believe that screening of key prognostic genes for RT in patients with RCC combined with renal failure

would be beneficial to provide more clinical options.

Our results suggest the idea that ACADM and SUCLA2 may be targets that influence the prognosis of patients with RCC combined with renal failure. Ducasa *et al.* (28-30) concurred with our view, which may be due to the fact that deletion of ACADM and SUCLA2 can lead to the accumulation of lipotoxic metabolites (e.g., ceramides) in the mitochondria, which induces mitochondrial membrane potential collapse and ROS overproduction, which ultimately activates apoptotic signaling in renal tubular epithelial cells. In addition, Sukonina *et al.* (31) also suggested that DLAT may affect survival in patients with renal disease, which is related to the fact that low expression of DLAT may weaken renal antioxidant defenses by inhibiting pyruvate dehydrogenase activity and reducing NADH production. Together, the above mechanisms lead to renal tubular energy metabolism failure and interstitial fibrosis, which may be an important molecular basis for renal failure after radiotherapy in renal cancer patients. Our results showed that these four genes were significantly under-expressed in both the renal cancer radiotherapy group and the renal failure group, suggesting that the inhibition of their expression may drive both acidification of the tumor microenvironment and renal tubulointerstitial fibrosis, and serve as a key molecular hub linking renal cancer progression and renal failure.

The ACADM gene encodes medium chain acyl coenzyme A dehydrogenase (MCAD), whose deficiency is one of the most common mitochondrial fatty acid oxidation disorders. Nochi *et al.* (32) showed that cells from patients with MCAD deficiency are more resistant to oxidative stress, which may be related to their enhanced antioxidant system. The SUCLG2 gene encodes the β subunit, which is an essential component of the tricarboxylic acid cycle. Donti *et al.* (33) found that deletion of SUCLG2 leads to mitochondrial DNA depletion and defects in the multiple respiratory chain, thereby affecting mitochondrial energy metabolism. The results of Jackson *et al.* (34) suggested that DLAT and SUCLA2 are important components of the pyruvate dehydrogenase complex (PDC) and succinyl coenzyme A synthetase, which converts pyruvate to acetyl coenzyme A in cellular metabolism, thereby linking glycolysis and the tricarboxylic acid cycle (TCA cycle). When PDC function is impaired, cells may compensate for this metabolic defect by increasing glycolysis and oxidative phosphorylation (35). Taken together, we suggest that the metabolic imbalance induced by these four genes may indirectly regulate immune cell epigenetic modification and inflammatory signaling activation by altering the abundance of mitochondrial metabolic intermediates (e.g., α -ketoglutarate, succinate), thus creating a vicious cycle of metabolic reprogramming and immune microenvironmental disruption.

Our findings revealed that GO and KEGG enrichment analysis of upregulated genes in the kidney cancer radiotherapy population compared to the normal population showed significant activation of T-cell activation (GO:0042110), cytokine-cytokine receptor interactions (hsa04060), and the NF- κ B pathway (hsa04064), suggesting that renal cancer radiotherapy may remodel the tumor immune microenvironment through pro-inflammatory factor release. The results of Vanpouille *et al.* (36) demonstrated that radiotherapy induces immunogenic death of tumor cells, thereby promoting cross-presentation of tumor antigens and activation of effector T cells. In addition, Filatenkov *et al.* (37) found that radiotherapy could also enhance the infiltration and activity of effector T cells by altering the expression of cytokines and chemokines in the tumor microenvironment. Wu *et al.* (38) suggested that radiotherapy may affect the tumor immune microenvironment by altering the phenotype of tumor-associated macrophages (TAMs) from the pro-tumorigenic M2 type to the anti-tumorigenic M1 type.

We found that down-regulated genes in patients with RCC combined with renal failure were significantly enriched in the mitochondrial matrix (GO:0005759) and basement membrane (GO:0005604), which was highly consistent with the clinical renal tubular atrophy and abnormal mitochondrial morphology. The results of Tang *et al.* also showed that mitochondrial dysfunction plays an important role in the pathogenesis of chronic kidney disease (CKD) and that the loss of mitochondrial mass Loss of control mechanisms may lead to mitochondrial damage and dysfunction, which may trigger cell death and tissue damage (39). In addition to this, a study by Galvan *et al.* proposed that morphological changes in mitochondria may be due to dysregulation of mitochondrial fusion and division processes, which are critical in maintaining mitochondrial function and cellular health (40). The findings of He *et al.* showing that a reduction in mitochondrial DNA copy number is associated with an increased risk of progression of chronic kidney disease further support the mitochondrial important role (41). These studies are consistent with our findings.

Our survival analysis confirmed that high expression of ACADM, DLAT, SUCLA2, and SUCLG2 was significantly and positively correlated with patients' overall survival (HR = 0.466-0.544), suggesting that they could be used as novel biomarkers for the efficacy of radiotherapy and prognosis of renal function in renal cancer. The combination of immune checkpoint inhibitors with radiotherapy may enhance therapeutic efficacy, especially in those tumors carrying programmed death ligand 1 (PD-L1) (42). The expression levels of these immune-related genes can be an important

indicator for assessing the efficacy of radiotherapy. Thus, the results of Ren et al. showed the importance of IANGPTL3, IL2RA, PPARA, SHC1, TGFA and TNFSF14 in monitoring and predicting the prognosis of ccRCC (43). The current study has not yet reached a unified conclusion and needs to be validated by animal and cellular experiments as well as large-scale cohort studies.

This study has some limitations. The first integrated GEO datasets were from different sequencing platforms, and batch effects may not have been completely eliminated despite the standardized process (RMA algorithm). Secondly the functional mechanisms of the target genes have not been validated by in vitro/in vivo experiments and independent clinical cohorts were not included to validate their causal relationship with the IBS-D phenotype. Finally, data association relies on published literature, which may miss negative results or emerging pathologic mechanisms, limiting the comprehensiveness of conclusions.

CONCLUSION

ACADM, *DLAT*, *SUCLA2* and *SUCLG2* may affect the prognosis of patients with RCC combined with renal failure. More clinical data and experiments are needed to validate the specific mechanisms of these genes in metabolic adaptive regulation and to explore combination therapy strategies targeting metabolic reprogramming.

Acknowledgments: We sincerely thank the conduct all authors for their invaluable help in this work. We extend our gratitude to Zibo First Hospital for their invaluable support in preparing this manuscript.

Ethical compliance: This study utilized de-identified genomic data from open-access repositories (including TCGA and GEO), which were ethically sourced and contained no identifiable private information. As no human/animal experiments were conducted, institutional ethics approval was exempted per national guidelines. Analytical workflows adhered to FAIR data principles, ensuring methodological rigor and reproducibility. Stringent measures were implemented to prevent any ethical violations or data misuse during computational analyses.

Conflict of interest : The authors declare that there are no potential conflicts of interest in this article. No AI assistance was used in the manuscript writing process.

Author contributions: J.W., and P.G., conceived and designed the research framework. Z.W., performed data acquisition from TCGA and public repositories, while L.F., conducted bioinformatics analysis and statistical validation. J.W., and P.G., drafted the initial manuscript with critical input from J.Z., who supervised the methodological rigor. All authors

collaboratively refined and approved the final manuscript version.

Funding : None.

REFERENCES

- Zhang S, Xiong X, Xie N, et al. (2024) The efficacy and safety of stereotactic body radiotherapy combined with systematic therapy for metastatic renal cell carcinoma: a systematic review and meta-analysis. *MedComm*, **5**: e544.
- Naik P, Dudipala H, Chen YW, et al. (2024) The incidence, pathogenesis, and management of non-clear cell renal cell carcinoma. *Therapeutic Advances in Urology*, **16**: 17562872241232578.
- Schafer EJ, Jemal A, Wiese D, et al. (2023) Disparities and trends in genitourinary cancer incidence and mortality in the USA. *European Urology*, **84**: 117-126.
- Yang J, Wang K, Yang Z (2023) Treatment strategies for clear cell renal cell carcinoma: Past, present and future. *Frontiers in Oncology*, **13**: 1133832.
- Tumkur Sitaram R, Landström M, Roos G, et al. (2021) Significance of PI3K signalling pathway in clear cell renal cell carcinoma in relation to VHL and HIF status. *Journal of Clinical Pathology*, **74**: 216-222.
- Kim CS, Kim B, Suh SH, et al. (2022) Risk of Kidney failure in patients with cancer: A South Korean population-based cohort study. *American Journal of Kidney Diseases*, **79**: 507-517.e501.
- Lai S, Mariotti A, Coppola B, et al. (2014) Uricemia and homocysteinemia: nontraditional risk factors in the early stages of chronic kidney disease--preliminary data. *European Review for Medical and Pharmacological Sciences*, **18**: 1010-1017.
- Jourde-Chiche N, Dou L, Cerini C, et al. (2011) Vascular incompetence in dialysis patients--protein-bound uremic toxins and endothelial dysfunction. *Seminars in Dialysis*, **24**: 327-337.
- Kadowaki T, Maegawa H, Watada H, et al. (2022) Interconnection between cardiovascular, renal and metabolic disorders: A narrative review with a focus on Japan. *Diabetes, Obesity & Metabolism*, **24**: 2283-2296.
- Wang S, Liu Z, Zhang D, et al. (2022) The incidence and risk factors of chronic kidney disease after radical nephrectomy in patients with renal cell carcinoma. *BMC Cancer*, **22**: 1138.
- Denic A, Elsherbiny H, Mullan AF, et al. (2020) Larger nephron size and nephrosclerosis predict progressive CKD and mortality after radical nephrectomy for tumor and independent of kidney function. *Journal of the American Society of Nephrology*, **31**: 2642-2652.
- Jung M, Choo E, Li J, et al. (2024) Longitudinal trends of comorbidities and survival among kidney cancer patients in Asian population. *Cancer Medicine*, **13**: e70421.
- Cai CF, He Y, Yue D, et al. (2023) DIRAS2 promotes radiation resistance in renal cell carcinoma via autophagy induction and MKK4-JNK1 pathway activation. *International Journal of Radiation Research*, **21**: 805-813.
- Buttiglierio C, Allis S, Tucci M, et al. (2018) Role of radiotherapy in improving activity of immune-modulating drugs in advanced renal cancer: Biological rationale and clinical evidences. *Cancer Treatment Reviews*, **69**: 215-223.
- Cerbone L, Rebuzzi SE, Lattanzi E, et al. (2020) Abscopal effect after hypofractionated radiotherapy in metastatic renal cell carcinoma pretreated with pazopanib. *Immunotherapy*, **12**(12): 869-878.
- Paciotti M, Schmidt AL, Ravi P, et al. (2021) Temporal trends and predictors in the use of stereotactic body radiotherapy for treatment of metastatic renal cell carcinoma in the U.S. *The Oncologist*, **26**: e905-e906.

17. Hosaka S, Katagiri H, Niwakawa M, et al. (2018) Radiotherapy combined with zoledronate can reduce skeletal-related events in renal cell carcinoma patients with bone metastasis. *International Journal of Clinical Oncology*, **23**: 1127-1133.
18. Pastor S, Rodríguez-Ribera L, Corredor Z, et al. (2018) Levels of DNA damage (Micronuclei) in patients suffering from chronic kidney disease. Role of GST polymorphisms. *Mutation Research*, **836**: 41-46.
19. Syed-Ahmed M and Narayanan M (2019) Immune dysfunction and risk of infection in chronic kidney disease. *Advances in Chronic Kidney Disease*, **26**: 8-15.
20. Zhao S, Ye Z, Stanton R (2020) Misuse of RPKM or TPM normalization when comparing across samples and sequencing protocols. *RNA (New York, NY)*, **26**: 903-909.
21. Ritchie ME, Phipson B, Wu D, et al. (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Research*, **43**: e47.
22. Diao C, Xi Y, Xiao T (2018) Identification and analysis of key genes in osteosarcoma using bioinformatics. *Oncology Letters*, **15**: 2789-2794.
23. Huang M, Yang Y, Zhu X, et al. (2021) A prospective phase II study of raltitrexed combined with S-1 as salvage treatment for patients with refractory metastatic colorectal cancer. *Asia Pac J Clin Oncol*, **17**: 513-521.
24. Scherer A, Günther OP, Balshaw RF, et al. (2013) Alteration of human blood cell transcriptome in uremia. *BMC Medical Genomics*, **6**: 23.
25. Nouhaud FX, Pfister C, Defortescu G, et al. (2015) Baseline chronic kidney disease is associated with toxicity and survival in patients treated with targeted therapies for metastatic renal cell carcinoma. *Anti-Cancer Drugs*, **26**: 866-871.
26. Zhang Z, Zhao J, Zabel J, et al. (2016) Proteinuria in patients undergoing renal cancer surgery: impact on overall survival and stability of renal function. *European Urology Focus*, **2**: 616-622.
27. Ohno Y, Nakashima J, Ohori M, et al. (2011) Impact of tumor size on renal function and prediction of renal insufficiency after radical nephrectomy in patients with renal cell carcinoma. *The Journal of Urology*, **186**: 1242-1246.
28. Ham J, Yun BH, Lim W, et al. (2021) Folpet induces mitochondrial dysfunction and ROS-mediated apoptosis in mouse Sertoli cells. *Pesticide Biochemistry and Physiology*, **177**: 104903.
29. Ducasa GM, Mitrofanova A, Fornoni A (2019) Crosstalk between lipids and mitochondria in diabetic kidney disease. *Current Diabetes Reports*, **19**: 144.
30. Woo CY, Baek JY, Kim AR, et al. (2020) Inhibition of ceramide accumulation in podocytes by myriocin prevents diabetic nephropathy. *Diabetes & Metabolism Journal*, **44**: 581-591.
31. Sukonina V, Ma H, Zhang W, et al. (2019) FOXK1 and FOXK2 regulate aerobic glycolysis. *Nature*, **566**: 279-283.
32. Nochi Z, Birkler RID, Fernandez-Guerra P, et al. (2020) Increased antioxidant response in medium-chain acyl-CoA dehydrogenase deficiency: does lipoic acid have a protective role? *Pediatric Research*, **88**: 556-564.
33. Donti TR, Stromberger C, Ge M, et al. (2014) Screen for abnormal mitochondrial phenotypes in mouse embryonic stem cells identifies a model for succinyl-CoA ligase deficiency and mtDNA depletion. *Disease Models & Mechanisms*, **7**: 271-280.
34. Jackson LE, Kulkarni S, Wang H, et al. (2017) Genetic dissociation of glycolysis and the TCA cycle affects neither normal nor neoplastic proliferation. *Cancer Research*, **77**: 5795-5807.
35. Wang H, Lu J, Kulkarni S, et al. (2019) Metabolic and oncogenic adaptations to pyruvate dehydrogenase inactivation in fibroblasts. *The Journal of Biological Chemistry*, **294**: 5466-5486.
36. Vanpouille-Box C, Pilonis KA, Wennerberg E, et al. (2015) In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. *Vaccine*, **33**: 7415-7422.
37. Filatenkov A, Baker J, Strober S (2016) Disruption of evasive immune cell microenvironment in tumors reflects immunity induced by radiation therapy. *Oncoimmunology*, **5**: e1072673.
38. Wu Q, Allouch A, Martins I, et al. (2017) Macrophage biology plays a central role during ionizing radiation-elicited tumor response. *Biomedical Journal*, **40**: 200-211.
39. Tang C, Cai J, Yin XM, et al. (2021) Mitochondrial quality control in kidney injury and repair. *Nature reviews Nephrology*, **17**: 299-318.
40. Galvan DL, Green NH, Danesh FR (2017) The hallmarks of mitochondrial dysfunction in chronic kidney disease. *Kidney International*, **92**: 1051-1057.
41. He WJ, Li C, Huang Z, et al. (2022) Association of mitochondrial DNA copy number with risk of progression of kidney disease. *Clinical journal of the American Society of Nephrology*, **17**: 966-975.
42. Nguyen NP, Chirila ME, Page BR, et al. (2024) Immunotherapy and stereotactic body radiotherapy for older patients with non-metastatic renal cancer unfit for surgery or decline nephrectomy: practical proposal by the International Geriatric Radiotherapy Group. *Frontiers in Oncology*, **14**: 1391464.
43. Ren S, Wang W, Shen H, et al. (2020) Development and validation of a clinical prognostic model based on immune-related genes expressed in clear cell renal cell carcinoma. *Frontiers in Oncology*, **10**: 1496.

